Stempoint Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Stempoint Capital’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,000	Closed	-$15.5K	–	75
2025 Q1	$15.5K	Buy	+10,000	New	+$555K	﹤0.01%	59

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Stempoint Capital's RYTM Position: Q1 2026 in Review

Stempoint Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 58,915 shares — an estimated $6.31M sold.

Stempoint Capital first reported a position in RYTM in Q3 2024 and held it in 6 quarters. The position peaked at $11.6M in Q4 2024. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

Stempoint Capital reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Stempoint Capital sold 58,915 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $6.31M.
Stempoint Capital first reported a position in Rhythm Pharmaceuticals in Q3 2024 and held it in 6 quarters.
Stempoint Capital's Rhythm Pharmaceuticals position peaked at $11.6M in Q4 2024.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.